Form 4: DeSantis Consolidates INBP Shares Under Controlled Entity

Damon DeSantis, a Director and 10% owner of Integrated BioPharma Inc., transferred over 1.3 million common shares to an entity he controls.

Summary

• Damon DeSantis, a Director and 10% owner of Integrated BioPharma Inc. (INBP), reported a transfer of common stock.
• On March 24, 2026, 1,356,293 shares of Common Stock were transferred from CD Financial, LLC to CDDS 2.0, LLC.
• Additionally, 7,392 shares of Common Stock were transferred from the Carl DeSantis Revocable Trust to CDDS 2.0, LLC on the same date.
• CDDS 2.0, LLC is a Florida limited liability company controlled by Damon DeSantis.
• The transactions were reported with a price of $0, indicating a transfer rather than a sale or purchase.
• Following these transactions, Damon DeSantis indirectly beneficially owns 1,363,685 shares through CDDS 2.0, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents an internal transfer of shares between entities controlled by the same individual, Damon DeSantis, and does not change his overall beneficial ownership or investment position in INBP.

Industry Context

StockSavvy.ai notes that such internal transfers among entities controlled by the same individual are common for estate planning or organizational restructuring and typically do not signal a change in investment thesis or company strategy within the broader biopharma industry.

Related Party Transactions

• The transactions involve the transfer of shares between entities (CD Financial, LLC and Carl DeSantis Revocable Trust) and CDDS 2.0, LLC, all of which are controlled by or related to the reporting person, Damon DeSantis.

Stakeholder Impact

• Shareholders: No direct impact on the total outstanding shares or the market's perception of the company's value, as beneficial ownership remains with the same individual.
• Management: No direct impact on company operations or strategic direction.
• Employees, Customers, Suppliers, Creditors: No discernible impact from this internal ownership restructuring.

Key Dates

Recommendation

This Form 4 reports an internal transfer of shares between entities controlled by Damon DeSantis, a director and 10% owner. It does not represent a sale or purchase in the open market and therefore does not signal a change in the insider's conviction or the company's fundamentals. As such, it provides no new information to warrant a change in investment recommendation, maintaining a 'hold' position for existing investors.

Keywords

Integrated BioPharma Inc., INBP, Damon DeSantis, SEC Form 4, Insider Transaction, Stock Transfer, Beneficial Ownership, Director, 10% Owner